134 related articles for article (PubMed ID: 35343865)
1. Mannose 2, 3, 4, 5, 6-
Bano S; Khan AB; Fatima S; Rashid Q; Prakash A; Gupta N; Ahmad I; Ansari S; Lynn AM; Abid M; Jairajpuri MA
J Biomol Struct Dyn; 2023 Jun; 41(9):3717-3727. PubMed ID: 35343865
[TBL] [Abstract][Full Text] [Related]
2. Depolymerized holothurian glycosaminoglycan with novel anticoagulant actions: antithrombin III- and heparin cofactor II-independent inhibition of factor X activation by factor IXa-factor VIIIa complex and heparin cofactor II-dependent inhibition of thrombin.
Nagase H; Enjyoji K; Minamiguchi K; Kitazato KT; Kitazato K; Saito H; Kato H
Blood; 1995 Mar; 85(6):1527-34. PubMed ID: 7888673
[TBL] [Abstract][Full Text] [Related]
3. Sucrose octasulfate selectively accelerates thrombin inactivation by heparin cofactor II.
Sarilla S; Habib SY; Kravtsov DV; Matafonov A; Gailani D; Verhamme IM
J Biol Chem; 2010 Mar; 285(11):8278-89. PubMed ID: 20053992
[TBL] [Abstract][Full Text] [Related]
4. Effects of antithrombin and heparin cofactor II levels on anticoagulation with Intimatan.
Tanaka KA; Szlam F; Vinten-Johansen J; Cardin AD; Levy JH
Thromb Haemost; 2005 Oct; 94(4):808-13. PubMed ID: 16270635
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of heparin cofactor II anticoagulant activity.
Bauman SJ; Church FC
J Biol Chem; 1999 Dec; 274(49):34556-65. PubMed ID: 10574918
[TBL] [Abstract][Full Text] [Related]
6. Antithrombotic potential of esculin 7, 3', 4', 5', 6'-O-pentasulfate (EPS) for its role in thrombus reduction using rat thrombosis model.
Ahmad I; Sharma S; Gupta N; Rashid Q; Abid M; Ashraf MZ; Jairajpuri MA
Int J Biol Macromol; 2018 Nov; 119():360-368. PubMed ID: 30009901
[TBL] [Abstract][Full Text] [Related]
7. Characterisation of the anticoagulant properties of a range of structurally diverse sulfated oligosaccharides.
Wall D; Douglas S; Ferro V; Cowden W; Parish C
Thromb Res; 2001 Aug; 103(4):325-35. PubMed ID: 11562342
[TBL] [Abstract][Full Text] [Related]
8. Structural features of heparin and their effect on heparin cofactor II mediated inhibition of thrombin.
Kim YS; Linhardt RJ
Thromb Res; 1989 Jan; 53(1):55-71. PubMed ID: 2922702
[TBL] [Abstract][Full Text] [Related]
9. Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma.
Tollefsen DM; Majerus DW; Blank MK
J Biol Chem; 1982 Mar; 257(5):2162-9. PubMed ID: 6895893
[TBL] [Abstract][Full Text] [Related]
10. Anticoagulant and antithrombin effects of intimatan, a heparin cofactor II agonist.
Buchanan MR; Brister SJ
Thromb Res; 2000 Sep; 99(6):603-12. PubMed ID: 10974347
[TBL] [Abstract][Full Text] [Related]
11. Role of thrombin anion-binding exosite-I in the formation of thrombin-serpin complexes.
Myles T; Church FC; Whinna HC; Monard D; Stone SR
J Biol Chem; 1998 Nov; 273(47):31203-8. PubMed ID: 9813026
[TBL] [Abstract][Full Text] [Related]
12. Heparin cofactor II significance for the inhibition of thrombin at the injured vessel wall.
Pasche B; Swedenborg J; Frebelius S; Olsson P
Thromb Res; 1991 Jun; 62(5):409-19. PubMed ID: 1896960
[TBL] [Abstract][Full Text] [Related]
13. The complete N-terminal extension of heparin cofactor II is required for maximal effectiveness as a thrombin exosite 1 ligand.
Boyle AJ; Roddick LA; Bhakta V; Lambourne MD; Junop MS; Liaw PC; Weitz JI; Sheffield WP
BMC Biochem; 2013 Mar; 14():6. PubMed ID: 23496873
[TBL] [Abstract][Full Text] [Related]
14. Anticoagulant properties of a sulfated galactan preparation from a marine green alga, Codium cylindricum.
Matsubara K; Matsuura Y; Bacic A; Liao M; Hori K; Miyazawa K
Int J Biol Macromol; 2001 Jun; 28(5):395-9. PubMed ID: 11325427
[TBL] [Abstract][Full Text] [Related]
15. Modulating the degree of fucosylation of fucosylated chondroitin sulfate enhances heparin cofactor II-dependent thrombin inhibition.
Xu L; Gao N; Xiao C; Lin L; Purcell SW; Wu M; Zhao J
Eur J Med Chem; 2018 Jun; 154():133-143. PubMed ID: 29787913
[TBL] [Abstract][Full Text] [Related]
16. Exosites 1 and 2 are essential for protection of fibrin-bound thrombin from heparin-catalyzed inhibition by antithrombin and heparin cofactor II.
Becker DL; Fredenburgh JC; Stafford AR; Weitz JI
J Biol Chem; 1999 Mar; 274(10):6226-33. PubMed ID: 10037709
[TBL] [Abstract][Full Text] [Related]
17. Structure and anticoagulant activity of fucosylated glycosaminoglycan degraded by deaminative cleavage.
Zhao L; Lai S; Huang R; Wu M; Gao N; Xu L; Qin H; Peng W; Zhao J
Carbohydr Polym; 2013 Nov; 98(2):1514-23. PubMed ID: 24053834
[TBL] [Abstract][Full Text] [Related]
18. Serpin-glycosaminoglycan interactions.
Rein CM; Desai UR; Church FC
Methods Enzymol; 2011; 501():105-37. PubMed ID: 22078533
[TBL] [Abstract][Full Text] [Related]
19. The heparin binding properties of heparin cofactor II suggest an antithrombin-like activation mechanism.
O'Keeffe D; Olson ST; Gasiunas N; Gallagher J; Baglin TP; Huntington JA
J Biol Chem; 2004 Nov; 279(48):50267-73. PubMed ID: 15371417
[TBL] [Abstract][Full Text] [Related]
20. Interaction of thrombin with heparin cofactor II and antithrombin III on prostacyclin production by cultured endothelial cells.
Kaji T; Itoh F; Hayakawa Y; Oguma Y; Sakuragawa N
Thromb Res; 1989 Oct; 56(1):99-107. PubMed ID: 2512688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
